08/05/2022 | Press release | Distributed by Public on 08/05/2022 14:53
August is National Immunization Awareness Month, intended to encourage people to stay up to date on necessary vaccinations. Because health risks associated with COVID-19 are mitigated by vaccines and boosters, this week's blog focuses on current understanding of COVID-19 and immune health.
As the COVID-19 pandemic continues with new cases on the rise, researchers are working to gain a better understanding of mechanisms underlying SARS-CoV-2 infection and immune factors that contribute to long COVID. Characterizing how immune cells respond to SARS-CoV-2 can help to identify therapeutic targets, develop next generation vaccines, and stratify patients at risk for severe COVID-19. That being said, many analytical techniques miss the critical cell attributes providing key functional data.
IsoPlexis' functional phenotyping platform, which uses multiplexed panels tailored for different immune applications, allows researchers to easily measure cytokine secretions at both single-cell and bulk levels. By characterizing immune cell function using IsoPlexis' IsoCode Single-Cell Secretome and CodePlex Secretome panels, researchers have uncovered mechanisms of how immune cells are associated with moderate and severe disease, factors contributing to long COVID, and more.
These findings and more COVID-19 studies are detailed in the IsoPlexis Proteomic Suite for COVID-19 App Note.
IsoPlexis' functional proteomics platform has been used across numerous research areas to gain unique insights into disease progression, treatment response and potency, and mechanisms of resistance. By combining multiplexed analysis with a streamlined workflow, IsoPlexis' proteomics platform lets researchers generate and analyze data with a fraction of the hands-on time of other systems, leading to accelerated research, deeper insights, and improved outcomes.